Table 1.
Baseline characteristics of patients selected for the validation cohort. Values are expressed as number (%) or mean ± SD.
| Variables | Validation cohort (N = 182) | |||
|---|---|---|---|---|
| Normal (n = 29) | CH (n = 28) | LC (n = 35) | HCC (n = 90) | |
| Age (years) | 34.4 ± 7.7 | 46.1 ± 10.7 | 53.5 ± 10.5 | 55.1 ± 9.0 |
| Male sex | 4 (13.8) | 15 (51.7) | 20 (58.8) | 71 (78.0) |
| Aspartate transaminase, IU·mL−1 | 16.62 ± 3.80 | 54.82 ± 52.25 | 82.29 ± 98.06 | 72.67 ± 96.80 |
| Alanine transaminase, IU·mL−1 | 13.86 ± 7.87 | 67.38 ± 78.21 | 78.14 ± 98.10 | 47.92 ± 58.98 |
| Platelet, ×109/L | 317 ± 35.84 | 185.15 ± 47.19 | 128.70 ± 76.64 | 166.41 ± 83.70 |
| AFP, ng·mL−1 | 1.78 ± 0.68 | 16.65 ± 24.30 | 65.88 ± 132.93 | 4246.40 ± 14450.97 |
| Etiology, hepatitis B virus/hepatitis C virus/alcohol/others | 27 (96.4)/1 (3.6)/0/0 | 30 (85.7)/3 (8.6)/2 (5.7)/0 | 82 (91.1)/4 (4.5))/3 (3.3)/1 (1.1) | |
| Albumin, g·L−1 | 4.55 ± 0.42 | 4.01 ± 0.53 | 4.26 ± 0.57 | |
| Bilirubin, mg·dL−1 | 0.82 ± 0.32 | 1.06 ± 0.99 | 1.39 ± 3.54 | |
| International normalized ratio | 1.17 ± 0.23 | 1.20 ± 0.10 | 1.49 ± 1.89 | |
| Modified Union for International Cancer Control stage, I/II/III/IVa/IVb | 32 (35)/14 (16)/26 (29) /11 (12)/ 7 (8) | |||